articleTop 1% cited
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
AIDS · 2000 · Vol. 14(4) · pp. F63–F67
Pablo Tebas✉(Diabetes Australia)William G. Powderly(Diabetes Australia)Sherry Claxton(Diabetes Australia)Donna Marin(Diabetes Australia)Woraphot Tantisiriwat(Diabetes Australia)Steven L. Teitelbaum(Diabetes Australia)Kevin E. Yarasheski(Diabetes Australia)
Abstract
Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.
HIV-related health complications and treatmentsBone and Joint DiseasesVitamin D Research StudiesOsteopeniaBone mineralOsteoporosisMedicineInternal medicineAdipose tissueBone densityGastroenterology
MeSH terms
AgedCross-Sectional StudiesDrug Therapy, CombinationHumansMaleMiddle AgedOsteoporosisAbsorptiometry, PhotonHIV InfectionsHIV Protease InhibitorsAnti-HIV Agents
Citations
541
FWCI
46.32
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review
AIDS · 2006 · 921 citations
References
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
AIDS · 1999 · 526 citations
Adverse effects of reverse transcriptase inhibitors
AIDS · 1998 · 848 citations
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
New England Journal of Medicine · 1998 · 9,489 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.